Monitor the AACR presentations for data on Zymeworks' preclinical or early clinical candidates, which could influence sentiment if results are compelling. No immediate catalyst for valuation change.
ZYME drugs
ZYME drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 18 $23.45entry
- T+1 · 8mo ago +1.90%α +2.16% · $23.90
- T+5 · 8mo ago +3.33%α +4.04% · $24.23
- T+20 · 7mo ago +15.99%α +9.94% · $27.20
- T+60 · 5mo ago −2.07%α −13.59% · $22.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zymeworks announced the acceptance of an oral presentation and six abstracts from its R&D portfolio for presentation at the 2026 AACR Annual Meeting. This highlights ongoing research activity but does not represent a material clinical or regulatory milestone.
Key Facts
- Zymeworks will present one oral presentation and six posters at the AACR Annual Meeting 2026.
- Presentations are from the company's wholly-owned R&D portfolio.
- Event takes place April 17–22, 2026, in San Diego, CA.
Financial Impact
No direct financial impact disclosed
Risk Factors
- Presented data may be preliminary or preclinical, with limited near-term commercial relevance.
- Lack of detailed results in the press release limits near-term trading catalyst potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257732 |
Track record
25 reports on ZYME
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
- Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
- Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers